Best wishes for 2021

We hope you and your family had a pleasant Holiday season. We wish to thank you for your support during a difficult 2020 and extend our best wishes for the New Year. At Pleco, we had to overcome some obstacles..

Read more..

R&D activities have started

Pleco Therapeutics has initiated a sponsored research program at The University of Texas MD Anderson Cancer Center based upon intellectual property developed at MD Anderson and licensed by Pleco. Despite the ongoing Covid pandemic, Pleco Therapeutics is now taking the..

Read more..

New non-executive director

Pleco is pleased to announce the appointment of Brenda Reynolds as member of its independent, non-executive board, effective 20th of May. Brenda has a background as a toxicologist and has extensive experience in global project management in the pharma sector...

Read more..

Announcement of non-executive team

Pleco is pleased to announce the appointment of Gerard van Leijenhorst, Debra Ainge and Callum Meikle to the non-executive board of directors. Gerard, Debra and Callum are all senior executives and bring a wealth of international experience in the pharmaceutical..

Read more..

Pleco signs license agreement with MD Anderson

Pleco Therapeutics has signed an agreement whereby Pleco licenses intellectual property developed at The University of Texas MD Anderson Cancer Center with the aim of developing innovative treatments for leukemia patients. MD Anderson is based in Houston, Texas and ranks..

Read more..

Pleco moves to new office at Pivot Park

Oss, 1st October 2019 – The Pleco team is pleased to announce that we have moved to our new office at Pivot Park in Oss, Noord-Brabant. The Pivot Park ecosystem consists of a vibrant pharmaceutical R&D community and offers an..

Read more..